Irinotecano (Irinotecan)

Irinotecan is a prodrug that is converted inside tumor cells to SN‑38, which inhibits DNA topoisomerase I. This inhibition prevents the re‑ligation of single‑strand DNA breaks during replication, leading to accumulation of DNA damage and ultimately causing tumor cell death.

The dose of Irinotecan is individualized and determined by the prescribing oncologist based on factors such as cancer type, treatment regimen, patient weight, organ function and prior therapy. Specific dosing schedules are not disclosed here and must follow the prescriber’s order.

Irinotecan is classified as Pregnancy Category D, indicating evidence of risk to the fetus. It should be avoided during pregnancy unless the potential benefit justifies the risk. Breastfeeding is not recommended because the drug can be excreted in breast milk and may harm the infant.

To order Irinotecano, submit an enquiry on the product page at gnhindia.com specifying the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including cold‑chain where required) and necessary import documentation.

Irinotecan belongs to the topoisomerase I inhibitor class, offering a distinct mechanism from oxaliplatin (a platinum compound) or fluoropyrimidines. Compared with topotecan, another topoisomerase I inhibitor, irinotecan is more commonly used in colorectal cancer regimens and has a different toxicity profile, especially regarding diarrhea and neutropenia.

Irinotecano should be stored at 2‑8 °C in a refrigerator, protected from light, and must not be frozen or shaken. The product should remain in its original packaging until use to maintain stability and sterility.

Irinotecano is administered intravenously by a qualified healthcare professional. It is typically given as an infusion over 30 to 90 minutes, depending on the prescribed regimen and patient tolerance. Administration must follow aseptic technique and institutional chemotherapy safety guidelines.

The most serious risks include severe neutropenia with fever (febrile neutropenia), life‑threatening diarrhea or colitis, hepatic toxicity, and rare allergic reactions such as anaphylaxis. Patients should be monitored closely for signs of infection, gastrointestinal distress and liver function abnormalities.

Irinotecano is contraindicated in patients with known hypersensitivity to irinotecan or any of its excipients, in those with severe hepatic impairment, and in individuals who are homozygous for the UGT1A1*28 allele without dose adjustment. Caution is also advised for patients with compromised bone‑marrow function.